Anika's Lean Turnaround Takes Hold: Margins Expand, Guidance Raised

Gross margin reaches 65%, highest EBITDA since 2020, and management raises full-year outlook while refining 2027 revenue guidance.

ANIK · Earnings Call · 2026-07-29

A Strong Quarter: Execution Delivers

Anika Therapeutics reported a strong second quarter: total revenue rose 16% to $32.6 million, with commercial channel up 17% and OEM up 14%. International revenue reached a record $12.6 million, up 22%. More importantly, gross margin expanded to 65% from 51% a year ago, and adjusted EBITDA hit $7.1 million — the highest since 2020. Management raised full-year revenue growth to 5-10% (from 1-9%) and adjusted EBITDA margin to 13-17% (from 5-10%). The market has rewarded the momentum, with the stock up nearly 48% over the past three months. “The second quarter marks great progress in our efforts to build a stronger, more profitable Anika.” — Stephen D. Griffin, President and Chief Executive Officer · 2026-07-29 These results reflect execution on the three strategic priorities CEO Steve Griffin set in February: accelerating sustainable revenue growth, driving operational excellence, and advancing the hyaluronic acid-based innovation pipeline.

Operational Excellence: The Lean Transformation

The margin expansion is no accident. Griffin highlighted the lean transformation as a critical driver, with projects doubling throughput on the Monovisc/CINGAL line and improving yield on OrthoVisc. In response to a question on sustainability, he affirmed:

I would say in short, yes. Think the mid-60s is where you could expect us to operate at. ... We are really, really proud of that work.
Stephen D. Griffin, President and Chief Executive Officer · 2026-07-29

This is the third consecutive quarter of mid-60s gross margin, and management believes it is structural. The company is in the early innings of its lean journey, with a long pipeline of improvement projects. As Griffin noted, “What you heard me say is accurate is that second half of the year, we expect to see sort of that 64% range.” — Stephen D. Griffin, President and Chief Executive Officer · 2026-07-29 He echoed earlier confidence: in the first quarter call, he said, “I think the first quarter is a demonstration of what we can do...” — Stephen Griffin, Chief Executive Officer · 2026-04-29 While G&A restructuring is largely behind them, manufacturing productivity still offers significant headroom. The company has also reduced stock-based compensation by 28% and completed a $15 million share repurchase, shrinking the share count to its lowest in over 50 years. Gross profit rose 29% year-over-year to $19 million, with the first-half margin expanding over 1,400 basis points.

Pipeline and Guidance: New Discipline

On the regulatory front, Hyalofast remains in active PMA review, with the company expecting to complete its deficiency letter response in the coming weeks. CINGAL's bioequivalence study is on track for completion around year-end, with CMC activities likely the final workstream before NDA submission. A notable change: the company is adopting a new revenue guidance practice for 2027, excluding any potential U.S. Hyalofast sales from the projection. This is a more conservative approach, acknowledging the uncertainty of FDA approval. As Ian McLeod explained: “Our outlook now excludes the previously implied $3 million of Hyalofast sales in the U.S.” — Ian W. McLeod, Senior Vice President, Chief Accounting Officer, and Treasurer · 2026-07-29 This discipline is reflected in the 2027 revenue guidance of 0-5% growth. In prior calls, management had included the $3 million in guidance — Griffin said in February, “We had previously shared that we had included about $3 million of anticipated revenue for Hyalofast in '27.” — Stephen Griffin, Chief Executive Officer · 2026-02-26 The new practice signals a more rigorous stance. The company also extended its credit facility, reducing the size while adding an accordion feature, preserving flexibility. Cash flow remains a lag, but management attributes this to order timing and inventory build, expecting positive free cash flow in the second half. Griffin: “It is absolutely an expectation of ours that over time, we generate stronger free cash flow and probably more of a conversation for 2027 and beyond.” — Stephen D. Griffin, President and Chief Executive Officer · 2026-07-29